Decahydro-2-methyl-2,6-naphthyridine | 933687-83-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: Decahydro-2-methyl-2,6-naphthyridine
• 英文别名: 6-methyl-2,3,4,4a,5,7,8,8a-octahydro-1H-2,6-naphthyridine
• CAS: 933687-83-3
• 化学式: C₉H₁₈N₂
• 分子量: 154.25
• InChiKey: VHJTWFIDPZHEDI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• CHEMICALLY ACTIVATED WATER-SOLUBLE PRODRUG
  申请人：SUMITOMO DAINIPPON PHARMA CO., LTD

  公开号：US20200207782A1

  公开（公告）日：2020-07-02

  The present invention addresses the problem of providing a novel chemically activated water-soluble prodrug. The present invention provides a compound represented by formula (1), or a pharmacologically acceptable salt thereof (in the formula, A represents A-0; X 1 and X 2 are the same as or different from each other and each independently represent a hydroxyl group or —O—C(═O)—Y—(C(R 1A ) (R 1B ))n-NH—R 2 , where X 1 and X 2 are not simultaneously hydroxyl groups, n is 2, 3, or 4, Y represents an oxygen atom or —NR 4 , R 1A and R 1B are the same as or different from each other and each independently represent a hydrogen atom, etc., and R 2 represents a hydrogen atom, etc.; and R a to R d are optionally present, are the same as or different from each other, and each independently represent a hydrogen atom, etc.).

  本发明解决了提供一种新型化学活化的水溶性前药的问题。本发明提供了由式（1）表示的化合物，或其药理学上可接受的盐（在该式中，A代表A-0；X1和X2彼此相同或不同，每个独立地代表一个羟基或—O—C(═O)—Y—(C(R1A)(R1B))n-NH—R2，其中X1和X2不同时是羟基，n为2、3或4，Y代表氧原子或—NR4，R1A和R1B彼此相同或不同，每个独立地代表氢原子等，R2代表氢原子等；以及Ra到Rd可选地存在，彼此相同或不同，每个独立地代表氢原子等）。
• HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS
  申请人：Reddy Panduranga Adulla P.

  公开号：US20120208826A1

  公开（公告）日：2012-08-16

  The present invention relates to heterocyclic amide derivatives of Formula (I): Formula (I) wherein the variables are as defined in the specification. The present invention further relates to compositions comprising said heterocyclic amide derivatives of formula (I) and methods for using said heterocyclic amide derivatives of formula (I) for treating or preventing a disease or disorder related to the activity of a protein kinase, in particular, a proliferative disease, an anti-proliferative disorder, inflammation, arthritis, a neurological or neurodegenerative disease, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease or a fungal infection.

  本发明涉及式(I)的杂环酰胺衍生物：式(I)其中变量如规范中所定义。本发明还涉及包含式(I)的上述杂环酰胺衍生物的组合物以及使用式(I)的上述杂环酰胺衍生物治疗或预防与蛋白激酶活性相关的疾病或障碍的方法，特别是增生性疾病、抗增生性障碍、炎症、关节炎、神经系统或神经退行性疾病、心血管疾病、脱发、神经疾病、缺血性损伤、病毒性疾病或真菌感染。
• BICYCLIC DIAMINES AS JANUS KINASE INHIBITORS
  申请人：Guerin David Joseph

  公开号：US20130225577A1

  公开（公告）日：2013-08-29

  The instant invention provides compounds of formula I which are Jak inhibitors, and as such are useful for the treatment of Jak-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.

  本发明提供了公式I的化合物，这些化合物是Jak抑制剂，因此对于治疗Jak介导的疾病如类风湿性关节炎、哮喘、慢性阻塞性肺疾病和癌症有用。
• Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer
  申请人：BOSTON BIOMEDICAL, INC.

  公开号：US10183925B2

  公开（公告）日：2019-01-22

  The present invention provides compounds represented by formula (1A), or pharmaceutically acceptable salts. Compounds represented by formula (1A), or pharmaceutically acceptable salts thereof, wherein A1 and A2 are identical or different, and each independently —C(═O) B, —C(═O)CR3AR3BB, —CO2B, —C(═S)OB, —CONR3CB, —C(═S)NR3CB, a hydrogen atom, or the like, wherein A1 and A2 are not both hydrogen atoms, wherein B is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocyclic group, an optionally substituted 3- to 12-membered cyclic amino group, or a group represented by the following formula (B), wherein the 3- to 12-membered monocyclic or polycyclic heterocyclic group and the 3- to 12-membered cyclic amino group have at least one or more secondary nitrogen atoms in the ring; R1 is a hydrogen atom or the like; R2A, R2B, R2C, and R2D are identical or different, and each independently a hydrogen atom or the like; and R8 is alkyl. wherein * denotes a bonding position.

  本发明提供了式(1A)代表的化合物或其药学上可接受的盐。由式(1A)代表的化合物或其药学上可接受的盐，其中A1和A2相同或不同，且各自独立地为-C(═O)B、-C(═O)CR3AR3BB、-CO2B、-C(═S)OB、-CONR3CB、-C(═S)NR3CB、氢原子或类似物，其中A1和A2并非都是氢原子、其中 B 是任选取代的 3 至 12 元单环或多环杂环基团，任选取代的 3 至 12 元环状氨基基团，或下式（B）所代表的基团，其中 3 至 12 元单环或多环杂环基团和 3 至 12 元环状氨基基团在环中至少有一个或多个仲氮原子；R1为氢原子或类似物；R2A、R2B、R2C 和 R2D 相同或不同，且各自独立地为氢原子或类似物；以及 R8 为烷基。 其中 * 表示键合位置。
• [EN] HDAC INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF<br/>[FR] INHIBITEUR DE HDAC, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION<br/>[ZH] HDAC抑制剂及其制备方法和用途
  申请人：HITGEN INC

  公开号：WO2020216298A1

  公开（公告）日：2020-10-29

  本发明公开了一种式I所示的化合物、及其立体异构体、及其在药学上可接受的盐。本发明还涉及含有式I化合物的药物组合物以及该化合物在制备HDAC抑制剂类药物中的用途。本发明的化合物或其药物组合物可以用于治疗细胞增殖疾病、自身免疫疾病、炎症、神经变性疾病或病毒性疾病。